• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies.

作者信息

Wu Jiaqi, Song Huaxin, Xiao Shujun, Lu Min

机构信息

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

Nat Rev Cancer. 2025 May 16. doi: 10.1038/s41568-025-00826-7.

DOI:10.1038/s41568-025-00826-7
PMID:40379968
Abstract
摘要

相似文献

1
Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies.TP53突变的异质性使得有必要通过p53挽救疗法进行区分。
Nat Rev Cancer. 2025 May 16. doi: 10.1038/s41568-025-00826-7.
2
Reply to 'Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies'.对“TP53突变的异质性使得采用p53挽救疗法时必须加以区分”的回复
Nat Rev Cancer. 2025 May 16. doi: 10.1038/s41568-025-00825-8.
3
Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry.通过即时护理p53免疫组织化学早期识别骨髓增生异常肿瘤和急性髓系白血病中的TP53突变及TP53等位基因状态。
Cancer. 2025 Jul 1;131(13):e35950. doi: 10.1002/cncr.35950.
4
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.低负担的 TP53 突变是 CLL 中常见的遗传事件，增加了治疗起始的风险。
J Pathol Clin Res. 2024 Jan;10(1):e351. doi: 10.1002/cjp2.351. Epub 2023 Nov 21.
5
Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.宫颈癌腺癌和鳞癌中 TP53 基因突变：系统评价。
Gynecol Oncol. 2013 Mar;128(3):442-8. doi: 10.1016/j.ygyno.2012.11.017. Epub 2012 Nov 17.
6
The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.TP53突变在食管腺癌中的预后价值：一项系统评价和荟萃分析。
Gut. 2017 Mar;66(3):399-410. doi: 10.1136/gutjnl-2015-310888. Epub 2016 Jan 5.
7
Heterogeneity of Mutations and P53 Protein Residual Function in Cancer: Does It Matter?癌症中突变的异质性与P53蛋白残余功能：这重要吗？
Front Oncol. 2020 Oct 28;10:593383. doi: 10.3389/fonc.2020.593383. eCollection 2020.
8
Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis.将MDM2抑制剂RG7388重新用于治疗TP53突变的非小细胞肺癌：通过ROS/p-p38/NOXA/半胱天冬酶-3/GSDME轴的一种不依赖p53的细胞焦亡机制。
Cell Death Dis. 2025 Jun 17;16(1):452. doi: 10.1038/s41419-025-07770-2.
9
Germline TP53 p.R337H and XAF1 p.E134* Variants: Prevalence in Paraguay and Comparison with Rates in Brazilian State of Paraná and Previous Findings at the Paraguayan-Brazilian Border.种系TP53 p.R337H和XAF1 p.E134*变异：巴拉圭的患病率及其与巴西巴拉那州患病率的比较以及巴拉圭-巴西边境地区既往研究结果对比
Curr Oncol. 2025 Jun 6;32(6):333. doi: 10.3390/curroncol32060333.
10
Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.日本高危急性髓系白血病患者基因突变与预后的关联：NS-87/CPX-351的1/2期研究
Int J Hematol. 2025 Feb 27. doi: 10.1007/s12185-025-03956-8.

引用本文的文献

1
Reply to 'Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies'.对“TP53突变的异质性使得采用p53挽救疗法时必须加以区分”的回复
Nat Rev Cancer. 2025 May 16. doi: 10.1038/s41568-025-00825-8.

本文引用的文献

1
Characterization of the generic mutant p53-rescue compounds in a broad range of assays.广泛的检测中通用突变型 p53 挽救化合物的特性。
Cancer Cell. 2024 Mar 11;42(3):325-327. doi: 10.1016/j.ccell.2024.01.008. Epub 2024 Feb 22.
2
Translating p53-based therapies for cancer into the clinic.将基于 p53 的癌症疗法转化为临床应用。
Nat Rev Cancer. 2024 Mar;24(3):192-215. doi: 10.1038/s41568-023-00658-3. Epub 2024 Jan 29.
3
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.
不同的 p53 突变对 ATO 的挽救能力是由内在的突变特性预先决定的。
Sci Transl Med. 2023 Apr 5;15(690):eabn9155. doi: 10.1126/scitranslmed.abn9155.
4
Targeting p53 pathways: mechanisms, structures, and advances in therapy.靶向 p53 通路：机制、结构和治疗进展。
Signal Transduct Target Ther. 2023 Mar 1;8(1):92. doi: 10.1038/s41392-023-01347-1.
5
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).小分子甲撑喹啉酮（MQ）激活致癌 p53 突变体的结构基础。
Nat Commun. 2021 Dec 3;12(1):7057. doi: 10.1038/s41467-021-27142-6.
6
Structural and Drug Targeting Insights on Mutant p53.突变型p53的结构与药物靶向见解
Cancers (Basel). 2021 Jul 3;13(13):3344. doi: 10.3390/cancers13133344.
7
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.三氧化二砷通过隐秘变构位点挽救结构 p53 突变。
Cancer Cell. 2021 Feb 8;39(2):225-239.e8. doi: 10.1016/j.ccell.2020.11.013. Epub 2020 Dec 24.
8
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.治疗性靶向 p53：所有突变体都平等，但有些突变体比其他突变体更平等。
Nat Rev Clin Oncol. 2018 Jan;15(1):13-30. doi: 10.1038/nrclinonc.2017.151. Epub 2017 Sep 26.
9
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.p53 通路：起源、癌症中的失活以及新兴治疗方法。
Annu Rev Biochem. 2016 Jun 2;85:375-404. doi: 10.1146/annurev-biochem-060815-014710. Epub 2016 May 4.
10
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.一种低分子量化合物使突变型p53的肿瘤抑制功能得以恢复。
Nat Med. 2002 Mar;8(3):282-8. doi: 10.1038/nm0302-282.